From ONCY's Nov10th PC presentation: CR=1, PR=8, SD=2 & PD=2
Best responses for the 13 evaluable patients at cut-off date: CR=1, PR=8, SD=2 and PD=2. Of the 9 patients with CR or PR, 7 responses were confirmed by a subsequent scan. ORR and clinical benefit rate (CBR) are 69% and 85%, respectively. Largest tumor diameter decreased from 30 mm at baseline to too small to measure at Week 24.
CR = Complete Response
PR = Partial Response
SD = Stable Disease
PD= Progressive Disease
Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Interim results from the GOBLET study
https://d1io3yog0oux5.cloudfront.net/_49089d0d8841cc5be0939bfc3b03e4bf/oncolyticsbiotech/db/343/2602/pdf/2022+GOBLET+SITC+Final.pdf